Chimeric human immunodeficiency virus (HIV) immunogens comprising GAG P24-P17 fused to multiple cytotoxic T lymphocyte (CTL) epitopes
US7993651B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 22, 2000 |
| Grant date | Aug 9, 2011 |
| Priority date | — |
| Expiry date | Sep 27, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16222
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is an immunogen in sterile form suitable for administration to a human subject, the immunogen comprising: at least a portion of the gag protein of HIV, said gag protein being from an HIV clade or having a consensus sequence for one or more HIV clades, and comprising at least parts of p17 and p24; and a synthetic polypeptide comprising a plurality of amino acid sequences, each sequence comprising a human CTL epitope of an HIV protein, and wherein a plurality of HIV proteins are represented in the synthetic polypeptide, said CTL epitopes being selected to stimulate an immune response to one or more HIV clades of interest.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.